Feature | June 16, 2014

SCAI Publishes Expert Recommendations for Most Common Form of Peripheral Artery Disease

Second in appropriate use series provides guidance on treatment for blocked arteries above the knee

June 16, 2014 — New appropriate use expert consensus documents developed by the Society for Cardiovascular Angiography and Interventions (SCAI) provide guidance on treating the most common form of peripheral artery disease (PAD), namely blockages that affect arteries above the knee. The paper e-published in Catheterization & Cardiovascular Interventions is the second in a series of PAD treatment recommendations released by SCAI. The series is aimed at helping physicians determine treatment options for the growing number of patients impacted by PAD.

The newly published criteria address PAD in the femoropopliteal (FP) segment, the most common location of the disease. While most people with FP disease are asymptomatic, some patients whose severe blockages markedly reduced blood flow experience impaired walking, a condition known as intermittent claudication. Patients with more extensive blockages may develop critical limb ischemia in which the limb is threatened and may need amputation. These patients classically have blockages both above and below the knee. Patients with long-standing diabetes and/or chronic kidney disease and the elderly are most at risk of developing such blockages. As the population ages and number of patients with diabetes rises, the rate of critical limb ischemia is expected to grow.

“Our goal in treating patients with femoropopliteal disease is to reduce pain, improve walking ability and enhance quality of life,” said Douglas E. Drachman, M.D., FSCAI, director of the Cardiology Fellowship Program at Massachusetts General Hospital and senior author of the consensus paper. “As technology has advanced, there are now safe and effective endovascular treatment options for a range of patients, not just those at high surgical risk.”

An expert panel developed the new recommendations by reviewing scientific data available on each treatment option. The panel found that balloon angioplasty continues to be a valid treatment, but with suboptimal long-term results in patients with long blockages, critical limb ischemia, diabetes or areas of complete blockage. The paper discusses use of self-expanding stents, covered stents and non-stenting alternatives, including atherectomy, in which obstruction is relieved by extracting arterial plaque.

The expert consensus document is the second in SCAI’s series of appropriate use recommendations for treating PAD. The earlier document, “Appropriate Use Criteria: A Society for Cardiovascular Angiography and Interventions (SCAI) Consensus Statement for Aorto-Iliac Arterial Intervention,” was published in May 2014.  Forthcoming publications, addressing infrapopliteal PAD and renal artery stenosis, will be published in Catheterization & Cardiovascular Interventions later this summer.

“As the incidence of PAD grows, SCAI is committed to helping physicians provide the best treatment options for the patient’s own condition and treatment goals,” said SCAI 2014-15 President Charles Chambers, M.D., FSCAI. “We want to help physicians find the safest treatment option that provides the greatest relief and improves quality of life.”

The paper, titled “Appropriate Use Criteria: A Society for Cardiovascular Angiography and Interventions (SCAI) Consensus Statement for Femoral-Popliteal Arterial Intervention,” is published in Catheterization & Cardiovascular Interventions.

For more information: www.scai.org

Related Content

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
Overlay Init